The 36-month beta value for EDIT is at 1.97. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 9 as “hold,” and 0 as “sell.”
The public float for EDIT is 82.93M, and currently, shorts hold a 15.30% of that float. The average trading volume for EDIT on April 22, 2025 was 3.75M shares.
EDIT) stock’s latest price update
The stock price of Editas Medicine Inc (NASDAQ: EDIT) has jumped by 12.78 compared to previous close of 1.33. Despite this, the company has seen a gain of 13.64% in its stock price over the last five trading days. zacks.com reported 2025-04-04 that Editas (EDIT) reported earnings 30 days ago. What’s next for the stock?
EDIT’s Market Performance
Editas Medicine Inc (EDIT) has seen a 13.64% rise in stock performance for the week, with a 14.50% gain in the past month and a 23.97% surge in the past quarter. The volatility ratio for the week is 9.95%, and the volatility levels for the past 30 days are at 9.78% for EDIT. The simple moving average for the past 20 days is 23.30% for EDIT’s stock, with a -43.84% simple moving average for the past 200 days.
Analysts’ Opinion of EDIT
Stifel gave a rating of “Hold” to EDIT, setting the target price at $3 in the report published on December 13th of the previous year.
EDIT Trading at 2.01% from the 50-Day Moving Average
After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.58% of loss for the given period.
Volatility was left at 9.78%, however, over the last 30 days, the volatility rate increased by 9.95%, as shares surge +4.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.00% upper at present.
During the last 5 trading sessions, EDIT rose by +9.85%, which changed the moving average for the period of 200-days by -68.88% in comparison to the 20-day moving average, which settled at $1.2140. In addition, Editas Medicine Inc saw 18.11% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EDIT starting from Lucera Erick, who sale 4,109 shares at the price of $1.71 back on Mar 04 ’25. After this action, Lucera Erick now owns 112,720 shares of Editas Medicine Inc, valued at $7,030 using the latest closing price.
O’Neill Gilmore Neil, the CEO of Editas Medicine Inc, sale 16,632 shares at $1.71 during a trade that took place back on Mar 04 ’25, which means that O’Neill Gilmore Neil is holding 295,474 shares at $28,452 based on the most recent closing price.
Stock Fundamentals for EDIT
Current profitability levels for the company are sitting at:
- -7.77 for the present operating margin
- 0.86 for the gross margin
The net margin for Editas Medicine Inc stands at -7.34. The total capital return value is set at -0.95. Equity return is now at value -98.10, with -56.40 for asset returns.
Based on Editas Medicine Inc (EDIT), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -6.0.
Currently, EBITDA for the company is -233.11 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 0.89. The receivables turnover for the company is 1.99for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.75.
Conclusion
In conclusion, Editas Medicine Inc (EDIT) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
